echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Johnson & Johnson's EGFR/c-Met dual antibody, the first new drug for specific mutations in lung cancer, was approved by the FDA for marketing

    Johnson & Johnson's EGFR/c-Met dual antibody, the first new drug for specific mutations in lung cancer, was approved by the FDA for marketing

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 21, the FDA issued an announcement to accelerate the approval of Johnson & Johnson's Rybrevant (amivantamab-vmjw) for patients with metastatic non-small cell lung cancer (NSCLC) who have advanced EGFR exon 20 insertion mutations after platinum-based chemotherapy.


    The approval is based on data from the CHRYSALIS study.


    The main efficacy endpoint is the overall response rate (ORR) and duration of response assessed by BICR according to RECIST 1.


    The most common adverse reactions (≥20%) are skin rash, infusion-related reactions, paronychia, musculoskeletal pain, dyspnea, nausea, fatigue, edema, stomatitis, cough, constipation and vomiting.


    Amivantamab (R&D code: JNJ-61186372) is an EGFR/c-Met double antibody developed by Johnson & Johnson.


    From: CDE official website

    According to the Insight database, Johnson & Johnson launched the EGFR/c-Met dual-antibody Amivantamab Phase III clinical trial in China in December last year, combined with the third-generation EGFR inhibitor Lazertinib for the first-line treatment of advanced unresectable NSCLC.


    From: Insight database (http://db.


    At present, in China, EGFR/c-Met dual antibodies, Betta Pharmaceuticals and Anmai Bio are in clinical development, and both of them have started a phase I/II clinical trial.


    Overview of domestic progress of EGFR/c-Met dual antibodies (Insight)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.